28/02/2014
ASX Announcement - Half Year Report to 31 December 2013
 
30/08/2013
Preliminary Final Report - period ending 30 June 2013
 
31/07/2013
ASX Announcement - Quarterly Report for Entities admitted on Basis of Commitments
 
17/07/2013
ASX Announcement - Capital Raising & Business Update
 
14/05/2013
ASX Announcement - Executive Director Appointment
 
01/05/2013
Appendix 4C - Quarterly Cash Flow Report
 
 

Welcome to Genera Biosystems

Genera Biosystems Limited is an Australian publicly listed company (ASX: GBI) that develops and commercialises multiplexed molecular diagnostic tests, based upon its proprietary AmpaSandTM bead-based technology. Genera's products compete in the global market for molecular diagnostic tests - currently valued at around US$2.6 billion, and expected to double in the next five years - and are used by commercial pathology providers. AmpaSand beads are an ideal platform for the kind of medium density multiplexed tests (5-150 analytes) of most use to pathology labs. Moreover, AmpaSand bead-based tests are high throughput, simple to use, and leverage existing laboratory infrastructure and expertise.

dnaclr.jpgcervclr.jpgpapclr.jpgcellsclr.jpglabclr.jpg

Genera's first product on sale is PapTypeTM, a highly competitive molecular diagnostic test for the simultaneous detection and genotyping of the 14 types human papillomavirus (HPV). The company has a number of other products in its development pipeline.

Genera manufactures its products at a custom-built facility in Melbourne, Australia.

Genera is also advanced in the development of a next-generation, ultra-sensitive, real-time detection system, which will have utility in a wide range of medical and non-medical applications.